<DOC>
	<DOC>NCT00932100</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of the REG1 anticoagulation System in Acute Coronary Syndrome (ACS) patients undergoing cardiac catheterization.</brief_summary>
	<brief_title>A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome</brief_title>
	<detailed_description>Primary Outcome Bleeding Secondary Outcome Ischemia</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Chest pain or other ischemic symptoms a minimum of 10 minutes in duration within 72 hours before anticipated cardiac catheterization; At least one of the following criteria are met: 1. New or presumably new STsegment depression of at least 1 mm or transient (30 minutes) STsegment elevation of at least 1 mm in 2 contiguous leads; 2. Elevated troponin I, T, or creatine phosphokinaseMB isoenzyme level within 24 hours of signing consent as defined by the universal MI definition 3. Documented coronary artery disease as evidenced on prior angiography, or by prior angioplasty, bypass graft surgery, or myocardial infarction Acute STsegment elevation myocardial infarct Anticipated inability to perform angiography within 24 hours of dosing Evidence of clinical instability Contraindications to anticoagulant use Recent cardiac intervention Clinically abnormal laboratory or test findings during screening Subject is pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>ACS</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Catheterization</keyword>
</DOC>